Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (Instituto Oncológico Dr Rosell)
- Development stage
- Phase 2
- Lead developer
- Instituto Oncológico Dr Rosell
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous dendritic cell vaccine developed by Instituto Oncológico Dr Rosell is an individualized biologic therapy designed for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The vaccine is produced by harvesting a patient's own dendritic cells via leukapheresis and pulsing them with irradiated autologous tumor cell lysate. This process allows the dendritic cells to present a broad spectrum of patient-specific tumor-associated antigens. When re-administered intradermally, these mature dendritic cells stimulate the immune system to mount a targeted T-cell response against the tumor. It is currently being evaluated in Phase Ib/II clinical trials as a maintenance therapy in combination with the checkpoint inhibitor atezolizumab following standard induction chemotherapy.
- Other names
- DCVautologous dendritic cell vaccine pulsed with irradiated autologous tumor cell lysate
Beyond the preview
Go deeper on autologous dendritic cell vaccine (Instituto Oncológico Dr Rosell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (Instituto Oncológico Dr Rosell).